{"id":9718,"date":"2021-04-28T10:38:32","date_gmt":"2021-04-28T08:38:32","guid":{"rendered":"https:\/\/ggba.swiss\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/"},"modified":"2023-07-04T13:43:36","modified_gmt":"2023-07-04T11:43:36","slug":"adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/","title":{"rendered":"ADC Therapeutics re\u00e7oit l&rsquo;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA"},"content":{"rendered":"<p>Le lymphome diffus \u00e0 grandes cellules B (DLBCL), le type de lymphome non hodgkinien le plus r\u00e9pandu aux \u00c9tats-Unis, est une maladie agressive \u00e0 progression rapide, h\u00e9t\u00e9rog\u00e8ne avec de multiples sous-types. Plus de 40 % des premiers traitements du DLBCL \u00e9chouent.<\/p>\n<p>Le traitement au stade avanc\u00e9 d&rsquo;<a href=\"https:\/\/adctherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">ADC Therapeutics<\/a>, ZYNLONTA, est le premier et le seul conjugu\u00e9 anticorps-m\u00e9dicament (ADC) ciblant le CD19 qui peut \u00eatre utilis\u00e9 en tant que traitement unique pour les patients adultes.<\/p>\n<p>Sur la base des taux de r\u00e9ponse positifs globaux obtenus au cours des essais cliniques, <a href=\"https:\/\/zynlontahcp.com\/\" target=\"_blank\" rel=\"noopener\">ZYNLONTA<\/a> a re\u00e7u une approbation acc\u00e9l\u00e9r\u00e9e du FDA (U.S. Food and Drug Administration).<\/p>\n<h4>Une \u00e9tape majeure pour ADC Therapeutics<\/h4>\n<p>Avec cette approbation, ZYNLONTA sera commercialis\u00e9 aux Etats-Unis sous peu. La soci\u00e9t\u00e9 bas\u00e9e au <a href=\"https:\/\/www.biopole.ch\/\" target=\"_blank\" rel=\"noopener\">Biop\u00f4le<\/a> d&rsquo;Epalinges (canton de Vaud) a \u00e9galement lanc\u00e9 l&rsquo;Advancing Patient Support Program, un programme complet de soutien aux patients offrant une aide financi\u00e8re, une formation continue et d&rsquo;autres ressources aux patients qui se voient prescrire ZYNLONTA.<\/p>\n<p>\u00ab\u00a0L&rsquo;approbation de ZYNLONTA par le FDA est une avanc\u00e9e enthousiasmante pour les patients atteints de DLBCL, et un \u00e9v\u00e9nement transformateur pour ADC Therapeutics\u00a0\u00bb, a d\u00e9clar\u00e9 Chris Martin, CEO d&rsquo;ADC Therapeutics. \u00ab\u00a0Nous exprimons notre plus profonde gratitude aux patients qui ont particip\u00e9 \u00e0 nos essais cliniques LOTIS-1 et LOTIS-2, \u00e0 leurs familles, aux chercheurs de l&rsquo;\u00e9tude et \u00e0 nos employ\u00e9s, car leur engagement a rendu possible cette \u00e9tape importante.\u00a0\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 de biotechnologie oncologique ADC Therapeutics a re\u00e7u la premi\u00e8re approbation du FDA pour ZYNLONTA, son traitement pour les patients adultes atteints de lymphome diffus \u00e0 grandes cellules B r\u00e9cidivant ou r\u00e9fractaire.<\/p>\n","protected":false},"author":3,"featured_media":9719,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1022,1065],"class_list":["post-9718","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr","tag-oncology-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADC Therapeutics re\u00e7oit l&#039;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics re\u00e7oit l&#039;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area\" \/>\n<meta property=\"og:description\" content=\"La soci\u00e9t\u00e9 de biotechnologie oncologique ADC Therapeutics a re\u00e7u la premi\u00e8re approbation du FDA pour ZYNLONTA, son traitement pour les patients adultes atteints de lymphome diffus \u00e0 grandes cellules B r\u00e9cidivant ou r\u00e9fractaire.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-28T08:38:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-04T11:43:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mathieu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"mathieu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\"},\"author\":{\"name\":\"mathieu\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"headline\":\"ADC Therapeutics re\u00e7oit l&rsquo;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA\",\"datePublished\":\"2021-04-28T08:38:32+00:00\",\"dateModified\":\"2023-07-04T11:43:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg\",\"keywords\":[\"Biotech\",\"Oncology\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\",\"name\":\"ADC Therapeutics re\u00e7oit l'approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg\",\"datePublished\":\"2021-04-28T08:38:32+00:00\",\"dateModified\":\"2023-07-04T11:43:36+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\"},\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg\",\"width\":630,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics re\u00e7oit l&rsquo;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab\",\"name\":\"mathieu\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/mathieu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics re\u00e7oit l'approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/","og_locale":"fr_FR","og_type":"article","og_title":"ADC Therapeutics re\u00e7oit l'approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area","og_description":"La soci\u00e9t\u00e9 de biotechnologie oncologique ADC Therapeutics a re\u00e7u la premi\u00e8re approbation du FDA pour ZYNLONTA, son traitement pour les patients adultes atteints de lymphome diffus \u00e0 grandes cellules B r\u00e9cidivant ou r\u00e9fractaire.","og_url":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2021-04-28T08:38:32+00:00","article_modified_time":"2023-07-04T11:43:36+00:00","og_image":[{"width":630,"height":380,"url":"https:\/\/staging.ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg","type":"image\/jpeg"}],"author":"mathieu","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"mathieu","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/"},"author":{"name":"mathieu","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"headline":"ADC Therapeutics re\u00e7oit l&rsquo;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA","datePublished":"2021-04-28T08:38:32+00:00","dateModified":"2023-07-04T11:43:36+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/"},"wordCount":261,"image":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg","keywords":["Biotech","Oncology"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/","url":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/","name":"ADC Therapeutics re\u00e7oit l'approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA - Greater Geneva Bern area","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg","datePublished":"2021-04-28T08:38:32+00:00","dateModified":"2023-07-04T11:43:36+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab"},"breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/06\/ADC-Zynlonta-630x380-3.jpg","width":630,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/adc-therapeutics-recoit-lapprobation-fda-traitement-lymphome-cancereux-zynlonta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics re\u00e7oit l&rsquo;approbation du FDA pour son traitement du lymphome canc\u00e9reux ZYNLONTA"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/de091cdfd7d8bce46f9b8b1cf9d868ab","name":"mathieu","url":"https:\/\/ggba.swiss\/fr\/author\/mathieu\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=9718"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9718\/revisions"}],"predecessor-version":[{"id":17918,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/9718\/revisions\/17918"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/9719"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=9718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=9718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=9718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}